🇺🇸 FDA
Patent

US 12097263

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

granted A61KA61K2039/505A61K47/60

Quick answer

US patent 12097263 (Muscle targeting complexes and uses thereof for treating myotonic dystrophy) held by Dyne Therapeutics, Inc. expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K47/60, A61K47/65, A61K47/6807